Biora Therapeutics Management

Management criteria checks 2/4

Biora Therapeutics' CEO is Adi Mohanty, appointed in Nov 2021, has a tenure of 2.5 years. total yearly compensation is $3.14M, comprised of 18.3% salary and 81.7% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth $105.55K. The average tenure of the management team and the board of directors is 2.3 years and 2.9 years respectively.

Key information

Adi Mohanty

Chief executive officer

US$3.1m

Total compensation

CEO salary percentage	18.3%
CEO tenure	2.5yrs
CEO ownership	0.4%
Management average tenure	2.3yrs
Board average tenure	2.9yrs

Recent management updates

Recent updates

Earnings Release: Here's Why Analysts Cut Their Progenity, Inc. (NASDAQ:PROG) Price Target To US$8.00

Mar 20

CEO Compensation Analysis

How has Adi Mohanty's remuneration changed compared to Biora Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$3m	US$574k	-US$124m
Sep 30 2023	n/a	n/a	-US$122m
Jun 30 2023	n/a	n/a	-US$64m
Mar 31 2023	n/a	n/a	-US$52m
Dec 31 2022	US$4m	US$550k	-US$49m
Sep 30 2022	n/a	n/a	-US$118m
Jun 30 2022	n/a	n/a	-US$140m
Mar 31 2022	n/a	n/a	-US$176m
Dec 31 2021	US$10m	US$63k	-US$179m

Compensation vs Market: Adi's total compensation ($USD3.14M) is above average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Adi's compensation has been consistent with company performance over the past year.

CEO

Adi Mohanty (56 yo)

2.5yrs

Tenure

US$3,139,017

Compensation

Mr. Aditya P. Mohanty, also known as Adi,M.B.A. serves as Chief Executive Officer and Director at Biora Therapeutics, Inc. (formerly known as Progenity, Inc.) since November 8, 2021. Mr. Mohanty founded En...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Aditya Mohanty	CEO & Director	2.5yrs	US$3.14m	0.45% $ 105.5k
Eric d'Esparbes	Chief Financial Officer	5yrs	US$1.60m	0.16% $ 38.7k
Clarke Neumann	Senior VP	9.7yrs	US$1.53m	0.14% $ 34.1k
Eric Fox	VP of Finance & Accounting & Treasurer	no data	no data	no data
George Gianakopoulos	Senior Vice President of Sales	4.6yrs	no data	no data
Robyn Hatton	Head of Human Resources	no data	no data	no data
Kevin Howe	Senior VP of Strategic Operations	no data	no data	no data
Sharat Singh	Head of Research	2.1yrs	no data	no data
Paul Shabram	Head of Technical Operations	2.1yrs	no data	no data
Ariella Kelman	Chief Medical Officer	less than a year	no data	no data
James Knight	Head of Business Development	less than a year	no data	no data

2.3yrs

Average Tenure

59yo

Average Age

Experienced Management: BIOR's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Aditya Mohanty	CEO & Director	2.5yrs	US$3.14m	0.45% $ 105.5k
Brian Kotzin	Independent Director	4.9yrs	US$185.11k	0.016% $ 3.8k
Anthony Lembo	Member of Clinical Advisory Board SIBO & Functional Bowel Disorders	no data	no data	no data
Geert D'Haens	Member of Inflammatory Bowel Disease Clinical Advisory Board	2.9yrs	no data	no data
Bruce Sands	Chairman of Inflammatory Bowel Disease Clinical Advisory Board	2.9yrs	no data	no data
Jeffrey Alter	Independent Chairman	5.3yrs	US$208.11k	0.018% $ 4.3k
Mark Pimentel	Member of Clinical Advisory Board - SIBO & Functional Bowel Disorders	no data	no data	no data
Lynne Powell	Independent Director	5.3yrs	US$163.11k	0.016% $ 3.8k
Severine Vermeire	Member of Inflammatory Bowel Disease Clinical Advisory Board	2.9yrs	no data	no data
Jill Howe	Independent Director	2.5yrs	US$180.11k	0.015% $ 3.5k
Satish Rao	Chair of Clinical Advisory Board-SIBO/Functional Bowel Disorders	no data	no data	no data
William Chey	Member of Clinical Advisory Board SIBO & Functional Bowel Disorders	no data	no data	no data

2.9yrs

Average Tenure

56yo

Average Age

Experienced Board: BIOR's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.

Biora Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Biora Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

High number of new and inexperienced directors

Biora Therapeutics, Inc.Appoints Bruce Sands as Chair of Its Clinical Advisory Board

Biora Therapeutics, Inc. Announces Board Appointment

High number of new and inexperienced directors

Progenity, Inc. Announces the Appointment of Paul Shabram as Senior Vice President, Technical Operations

Recent updates

Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose (Mad) Cohorts for Clinical Trial of BT-600

Biora Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development

Athyrium Capital Management Engages in Discussions with Biora Therapeutics

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million.

Biora Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $6.000003 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Biora Therapeutics, Inc. to Report Q4, 2023 Results on Mar 26, 2024

New major risk - Share price stability

Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose (Sad) Cohorts of Phase 1 Clinical Study of BT-600

Biora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of BT-600

Athyrium Capital Management Engages in Discussions with Biora Therapeutics

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

Biora Therapeutics, Inc. Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis

Consensus revenue estimates fall by 17%

Third quarter 2023 earnings released: US$4.89 loss per share (vs US$1.99 loss in 3Q 2022)

Biora Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Share price stability

Biora Therapeutics Presents Data on the Biojet™ Systemic Oral Delivery Platform At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Biora Therapeutics, Inc. (NasdaqGM:BIOR) acquired Interface Therapeutics Inc.

Biora Therapeutics Progresses Its BioJet™ Systemic Oral Delivery Platform

New major risk - Financial position

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biora Therapeutics, Inc. Announces New Patents Covering Its BioJet Systemic Oral Delivery Platform

Biora Therapeutics, Inc. Announces Clinical Device Performance Study Results for its NaviCap Targeted Oral Delivery Platform

Biora Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

An unknown large diagnostics company acquired Legacy Diagnostics Assets of Biora Therapeutics, Inc. (NasdaqGM:BIOR).

Biora Therapeutics Announces New Patents for Its NaviCap Targeted Oral Delivery Platform

Biora Therapeutics Presents Data on the BioJet Systemic Oral Delivery Platform at the American Diabetes Association 83rd Scientific Sessions

Biora Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $8 million.

First quarter 2023 earnings released: US$1.59 loss per share (vs US$1.98 loss in 1Q 2022)

Biora Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Biora Therapeutics Announces Improved Bioavailability Results for Its Systemic Delivery Platform

Biora Therapeutics Receives Compliance Letter from Nasdaq

Biora Therapeutics, Inc. Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn’s & Colitis Congress

Biora Therapeutics, Inc. Receives Feedback from the United States Food and Drug Administration on Its Clinical Development Plans for Its Pgn-600 Program

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

Athyrium Capital Engages in Discussions with Biora Therapeutics

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates increase by 20%

Price target increased to US$5.00

High number of new and inexperienced directors

Biora Therapeutics, Inc. has completed a Follow-on Equity Offering.

Biora Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Biora Therapeutics, Inc. Shares Data from Device Performance Study in Ulcerative Colitis Patients

Biora Therapeutics, Inc. Shares Preclinical Data on Oral Delivery of Biologics At the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference

Biora Therapeutics granted patent for oral delivery of GLP-1 receptor agonists

Biora Therapeutics, Inc.Appoints Bruce Sands as Chair of Its Clinical Advisory Board

Biora Therapeutics: Checking In On The Transformation

Second quarter 2022 earnings released: US$0.033 loss per share (vs US$0.65 loss in 2Q 2021)

Biora Therapeutics, Inc. Announces Successful Completion of Device Performance Study in Ulcerative Colitis Patients for Its Targeted Therapeutics Platform

Biora rallies 30%, highest since November on data for drug delivery device

Biora Therapeutics, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for Its Targeted Therapeutics Platform

Biora Therapeutics, Inc. Announces Board Appointment

Biora Therapeutics Receives Non-Compliance Notice from Nasdaq

First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.30 loss in 1Q 2021)

Biora Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target increased to US$8.00

High number of new and inexperienced directors

Progenity, Inc. Announces the Appointment of Paul Shabram as Senior Vice President, Technical Operations

Price target increased to US$8.00

Full year 2021 earnings released: US$1.86 loss per share (vs US$3.83 loss in FY 2020)

Progenity, Inc. Announces Departure of Damon Silvestry

Progenity: Analyzing The Huge Paradigm Shift

Progenity: Transformation Raises Questions

Progenity, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

Price target increased to US$6.33